18F-fluorodeoxyglucose PET/CT findings in pleural effusions of patients with known cancer;Identifikation maligner Pleura-Ergüsse mittels 18F-Fluordeoxyglukose-PET/CT - Eine Korrelation mit zytopathologischen Befunden

NuklearMedizin

Volumn 51, Issue 5, 2012, Pages 186-193

  Letovanec, I ^a   Allenbach, G ^b   Mihaescu, A ^a   Nicod Lalonde, M ^b   Schmidt, S ^b   Stupp, R ^b   Fitting, J W ^b   Boubaker, A ^b   Ris, H B ^b   Prior, John O ^b  

^a UNIVERSITY INSTITUTE OF PATHOLOGY   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

FDG; PET CT; Pleural effusion; Tumour

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BASOPHIL; BREAST CANCER; CANCER CELL; CELL COUNT; CLINICAL ARTICLE; COLORECTAL CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; EOSINOPHIL; ESOPHAGUS CANCER; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HEAD AND NECK CANCER; HUMAN; LUNG NON SMALL CELL CANCER; LYMPHOCYTE; LYMPHOMA; MACROPHAGE; MALE; MALIGNANT TERATOMA; MELANOMA; MESOTHELIOMA; NEUTROPHIL; PH; PLASMA CELL; PLEURA EFFUSION; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; METHODOLOGY; MIDDLE AGED; NEOPLASM; REPRODUCIBILITY;

FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PLEURAL EFFUSION; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84867301111     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.3413/Nukmed-0470-12-01     Document Type: Article

References (30)

1. Ahmad Z, Krishnadas R, Froeschle P. Pleural effusion: diagnosis and management. J Perioper Pract 2009; 19: 242-247.
2. Alkhawaldeh K, Biersack HJ, Henke A, Ezziddin S. Impact of dual-time-point 18F-FDG PET/CT in the assessment of pleural effusion in patients with nonsmall-cell lung cancer. Clini Nucl Med 2011; 36: 423-428.
3. Antony VB. Pleurodesis-testing the waters. Am Rev Respir Dis 1987; 135: 775-776.
4. Brenner H, Gefeller O. Variation of sensitivity, specificity, likelihood ratios and predictive values with disease prevalence. Stat Med 1997; 16: 981-991.
5. Brock MV, Hooker CM, Yung R et al. Can we improve the cytologic examination of malignant pleural effusions using molecular analysis? Ann Thorac Surg 2005; 80: 1241-1247.
6. Carretta A, Landoni C, Melloni G et al. 18FDG positron emission tomography in the evaluation of malignant pleural diseases-a pilot study. Eur J Cardiothorac Surg 2000; 17: 377-383.
7. Duysinx BC, Larock MP, Nguyen D et al. 18F-FDG PET imaging in assessing exudative pleural effusions. Nucl Med Commun 2006; 27: 971-976.
8. Edge SBB, Compton CC, Fritz AG et al. (eds). AJCC Cancer Staging Manual. Springer 2010; 646 p.
9. Erasmus JJ, McAdams HP, Rossi SE et al. FDG PET of pleural effusions in patients with non-small cell lung cancer. AJR Am J Roentgenol 2000; 175: 245-249.
10. Fischer B, Lassen U, Mortensen J et al. Preoperative staging of lung cancer with combined PET-CT. The N Engl J Med 2009; 361: 32-39.
11. Gamez C, Rosell R, Fernandez A et al. PET/CT fusion scan in lung cancer: current recommendations and innovations. J Thorac Oncol 2006; 1: 74-77.
12. Gupta NC, Rogers JS, Graeber GM et al. Clinical role of 18F-fluorodeoxyglucose positron emission tomography imaging in patients with lung cancer and suspected malignant pleural effusion. Chest 2002; 122: 1918-1924.
13. Heffner JE, Klein JS. Recent advances in the diagnosis and management of malignant pleural effusions. Mayo Clin Proc 2008; 83: 235-250.
14. Ishimori T, Saga T, Mamede M et al. Increased 18F-FDG uptake in a model of inflammation: concanavalin A-mediated lymphocyte activation. J Nucl Med 2002; 43: 658-663.
15. Jeong YJ, Kim S, Kwak SW et al. Neoplastic and nonneoplastic conditions of serosal membrane origin: CT findings. Radiographics 2008; 28: 801-818.
16. Kim BS, Kim IJ, Kim SJ et al. Predictive value of 18F-FDG PET/CT for malignant pleural effusion in non-small cell lung cancer patients. Onkologie 2011; 34: 298-303.
17. Kubota R, Yamada S, Kubota K et al. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992; 33: 1972-1980.
18. Light RW. Clinical practice. Pleural effusion. N Engl J Med 2002; 346: 1971-1977.
19. Love C, Tomas MB, Tronco GG, Palestro CJ. FDG PET of infection and inflammation. Radiographics 2005; 25: 1357-1368.
20. Maskell NA, Butland RJ. BTS guidelines for the investigation of a unilateral pleural effusion in adults. Thorax 2003; 58 (Suppl 2): ii8-ii17.
21. McGrath EE, Anderson PB. Diagnosis of pleural effusion: a systematic approach. Am J Crit Care 2011; 20: 119-127.
22. Mochizuki T, Tsukamoto E, Kuge Y et al. FDG uptake and glucose transporter subtype expressions in experimental tumor and inflammation models. J Nucl Med 2001; 42: 1551-1555.
23. Park SH, Goo JM, Jo CH. Receiver operating characteristic (ROC) curve: practical review for radiologists. Korean J Radiol 2004; 5: 11-18.
24. Poeppel TD, Krause BJ, Heusner TA et al. PET/CT for the staging and follow-up of patients with malignancies. Eur J Radiol 2009; 70: 382-392.
25. Schaffler GJ, Wolf G, Schoellnast H et al. Non-small cell lung cancer: evaluation of pleural abnormalities on CT scans with 18F FDG PET. Radiology 2004; 231: 858-865.
26. Starr RL, Sherman ME. The value of multiple preparations in the diagnosis of malignant pleural effusions. A cost-benefit analysis. Acta Cytol 1991; 35: 533-537.
27. Toaff JS, Metser U, Gottfried M et al. Differentiation between malignant and benign pleural effusion in patients with extra-pleural primary malignancies: assessment with positron emission tomographycomputed tomography. Invest Radiol 2005; 40: 204-209.
28. Wahl RL. To AC or not to AC: that is the question. J Nucl Med 1999; 40: 2025-2028.
29. Wicky S, Wintermark M, Schnyder P et al. Imaging of blunt chest trauma. Eur Radiol 2000; 10: 1524-1538.
30. Yoneda KY, Mathur PN, Gasparini S. The evolving role of interventional pulmonary in the interdisciplinary approach to the staging and management of lung cancer. Part III: diagnosis and management of malignant pleural effusions. Clin Lung Cancer 2007; 8: 535-547.